Skip to content

To Study The Effect Of Tilvak Ghrita Uttarbasti And Matrabasti In The Management Of Mootraghata (Benign Prostatic Hyperplasia)

A Clinico-Comparative Study Of Tilvak Ghrita Uttarbasti And Matrabasti In The Management Of Mootraghata (Benign Prostatic Hyperplasia) - NO

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032967
Enrollment
40
Registered
2021-04-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: Tilvak Ghrita Uttarbasti: Tilvak Ghrita Dose 20 ml Once in a Day For 21 Days (4 Cycle In One Cycle Uttarbasti For Continuous 3 Days Then 3 Days Gap Between Two Cycle) Control Interventi

Sponsors

Government Akhandanand Ayurved College Ahmedabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients presenting with classical signs and symptoms of Benign Prostatic Hyperplasia Controlled case of Diabetes mellitus (RBS upto 180 mg/dl) and Hypertension (upto 150/90 mmHg)

Exclusion criteria

Exclusion criteria: CA Prostate Urethral stricture Benign tumour of urethra Malignant tumour of urethra Urethral injury Urethral calculi Age above 80 years and below 40 years Patients with systemic diseases like uncontrolled Hypertension (more than 150/90 mmHg) and Uncontrolled Diabetes mellitus (RBS more than 180 mg/dl) Tuberculosis STD HIV HBsAg

Design outcomes

Primary

MeasureTime frame
Result will be assased on the basis of relief sign and symptoms of MootraghataTimepoint: 21 Days

Secondary

MeasureTime frame
Comparing the effect of both procedures in the management of MootraghataTimepoint: 21 Days

Countries

India

Contacts

Public ContactDr Harshit Shah

Government Akhandanand Ayurved College Ahmedabad

akhandanandprincipal@gmail.com9824068760

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026